Emcure Pharmaceuticals today announced the signing of a distribution agreement with Roche for select products in the nephrology and transplant medicine portfolio. The agreement marks a significant step toward expanding patient access to critical therapies in chronic kidney disease (CKD), anemia management, and transplant care across India. Under the agreement, which will be effective April 1, 2026, Emcure will distribute Roche’s established and globally recognised brands in the nephrology and transplant segment in India.

The agreement includes the following brands:

• CellCept – A globally leading immunosuppressant and original Roche innovation, supporting organ transplants worldwide since 1995.

• Mircera and Neorecormon – Proven therapies for anemia in chronic kidney disease, including Mircera’s long-acting ESA with dosing once every 2–4 weeks.

Commenting on the agreement, Satish Mehta, Managing Director & CEO, Emcure Pharmaceuticals, said, “This partnership with Roche is a natural extension of Emcure’s commitment to improving outcomes in anemia and renal care. Roche’s globally trusted innovations strongly complement our existing portfolio and reach. Together, we aim to expand access to these critical therapies and support physicians in delivering optimal care to patients across India.”

Rajji Mehdwan, Managing Director & CEO, Roche India & Neighbouring Markets, commented, “We are pleased to partner with Emcure Pharmaceuticals, a company with deep expertise and leadership in anemia management and nephrology. Through Emcure’s strong distribution network and clinical engagement, we believe these medicines can reach a larger number of patients who can benefit from Roche’s long-standing innovations in transplant and CKD care.”

The collaboration is aimed at improving patient access to proven therapies while supporting better anemia management and long-term outcomes for patients with CKD and transplant needs.